BTK inhibitor

Imbruvica (ibrutinib)

An approved treatment for Chronic Graft-versus-Host Disease and Waldenström Macroglobulinemia.

FDA Approved (2017)by Pharmacyclics / AbbVie / Janssen

Preclinical

Phase 1

Phase 2

Phase 3

Approved

2017

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Ibrutinib wherever you encounter it, plus the key facts at a glance.

Generic name: Ibrutinib
Brand name: Imbruvica
Development code: PCI-32765
Drug class: BTK inhibitor
Manufacturer: Pharmacyclics / AbbVie / Janssen
How it's taken: For patients 12 and older, 420mg by mouth once daily (capsules or tablets).

Ibrutinib blocks BTK, a protein that switches on B cells, and also ITK in T cells. It is also approved for adults with Waldenström macroglobulinemia, alone or with rituximab, and for chronic lymphocytic leukemia.

Follow Imbruvica by email

We'll email you when Imbruvica's FDA label changes, when the FDA acts on it, and when new trials for the condition you pick open. Unsubscribe anytime.

Condition to follow

You'll get, for Chronic Graft-versus-Host Disease:

Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month

Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Ibrutinib fits

Historic first: the first drug ever FDA-approved specifically for chronic GVHD (August 2017).

Approved after failure of one or more prior lines, positioning it as a second-line option alongside ruxolitinib.
Ruxolitinib (Jakafi), belumosudil (Rezurock) and axatilimab (Niktimvo) are also approved for chronic GVHD after earlier treatment, and no head-to-head trial has compared them with ibrutinib.

How Ibrutinib works

In chronic GVHD, donor B cells produce antibodies against the recipient's tissues while certain donor T cells directly attack organs. Two proteins act as 'on switches' for these immune cells: BTK activates B cells, and ITK activates specific T cell subsets. Ibrutinib permanently blocks both switches by forming an irreversible chemical bond with each protein.

With BTK blocked, B cells cannot produce the tissue-attacking antibodies. With ITK blocked, the pathogenic T cell subsets calm down.

In the pivotal study, 67% of patients with steroid-refractory cGVHD responded to ibrutinib, and among those who responded, most people whose skin, mouth or gut was affected saw that organ improve (88-91%).

Side effects and safety

What patients report

The label also warns about serious bleeding, infections, heart rhythm problems, heart failure and sudden death, high blood pressure, low blood counts, second cancers, liver injury, tumor lysis syndrome (a dangerous chemical imbalance when many cells break down at once), and harm to an unborn baby.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Ibrutinib

For Waldenström macroglobulinemia, adults take 420mg once a day, alone or with rituximab. The label says to avoid grapefruit and Seville oranges. Posaconazole and voriconazole, antifungal medicines often used after a transplant, call for a lower ibrutinib dose, and the label advises against most other strong CYP3A inhibitors^[4].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Imbruvica

With private insurance, the drugmaker's copay card can lower what you pay for Imbruvica. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 9 charity funds for the conditions it treats, 6 were open on October 26, 2026. Pick your insurance below to see which offers fit you.

Your insurance

From the drugmaker

Imbruvica (Ibrutinib)

IMBRUVICA By Your Side

Official program page Call 1-888-968-7743

Copay help
Eligible commercially insured patients may pay as little as $0 per prescription with the Copay Card; monthly maximums may apply.
For: private insurance · source
Insurance and case manager help
Nurse Support Line and Insurance Specialists explain benefits, estimate costs and find ways to lower costs for any insurance type, including no insurance.
For: private insurance, Medicare, Medicaid, no insurance · source

Good to know: Copay card excludes Medicare (including Part D and Advantage), Medicaid, TRICARE, DoD and VA. Uninsured patients can call IMBRUVICA By Your Side for help.

Checked on the drugmaker's official pages on September 24, 2026. Programs change; confirm with the program before you rely on it.

Charity funds

From a charity · TotalAssist (formerly PAN Foundation)
Graft-vs-Host Disease (GVHD) fund
Open
Apply on the foundation’s page
Pays for: Out-of-pocket costs for approved medications, up to $9,500 per year. Requires health insurance (any kind).
From a charity · NMDP (formerly Be The Match / National Marrow Donor Program)
NMDP Patient Financial Assistance Grants fund
Apply directly
Apply on the foundation’s page
Pays for: Out-of-pocket costs before and after blood or marrow transplant, ongoing GVHD treatment costs, clinical-trial travel and financial-crisis grants.
The foundation says: “Status not shown on page”
From a charity · Blood Cancer United (formerly The Leukemia & Lymphoma Society)
Clinical Trials Co-Pay Fund (all blood cancers) fund
Open
Apply on the foundation’s page
Pays for: Insurance premiums and treatment-related copays, deductibles and coinsurance, up to $3,500 per year. Requires health insurance (any kind).
From a charity · Blood Cancer United (formerly The Leukemia & Lymphoma Society)
Patient Aid Program fund
Open
Apply on the foundation’s page
Pays for: One-time $100 stipend for non-medical expenses (transportation, food, housing, utilities); no income or insurance requirement, up to $100 per year.
The foundation says: “CURRENT FUND STATUS: Open. Fund is currently Open.”
From a charity · HealthWell Foundation
Waldenstrom Macroglobulinemia fund
Open
Apply on the foundation’s page
Pays for: Copays, premiums or other treatment costs.
From a charity · NORD RareCare
IWMF Waldenstrom Macroglobulinemia Travel and Lodging Assistance fund
Open
Apply on the foundation’s page
Pays for: Travel and lodging for care.
The foundation says: “Accepting Applications”
From a charity · TotalAssist (formerly PAN Foundation)
Waldenstrom Macroglobulinemia fund
Open
Apply on the foundation’s page
Pays for: Out-of-pocket costs for approved medications, up to $9,500 per year. Requires health insurance (any kind).

Status as each foundation showed it on October 26, 2026.

Every program and charity fund for Chronic Graft-versus-Host Disease →

Every program and charity fund for Waldenström Macroglobulinemia →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Ibrutinib treatment timeline for Chronic Graft-Versus-Host Disease

Tap how long you have been on Ibrutinib to drop your pin on the road. Your answers stay on this device.

How long have you been on Ibrutinib?

Which form do you take?

Have you had blood counts and liver function tests checked since starting ibrutinib?

Anything you've noticed? Pick any that apply.

Answer the first 3 questions to see your plan.

Stage 1 of 5 · Start to 1 mo

Starting ibrutinib

You are starting ibrutinib for chronic GVHD that has not responded adequately to corticosteroids and possibly other therapies. For ages 12 and up, the cGVHD dose is 420mg once daily, taken at about the same time each day. Children 1 to 11 get a dose based on body size. Ibrutinib was the first drug ever approved specifically for cGVHD (August 2017), so doctors have years of experience with it. The drug blocks both BTK in B cells and ITK in T cells, targeting two arms of the immune attack driving your GVHD. During this first month, your team will monitor your blood counts, liver function, and watch for early side effects. Importantly, ibrutinib increases bleeding risk, so tell your doctor about any upcoming dental work, procedures, or if you are taking blood thinners or aspirin. You may also need an ECG because ibrutinib can occasionally cause atrial fibrillation. Ibrutinib can harm an unborn baby, so the label advises effective birth control during treatment and for 1 month after.

Coming up

In the PCYC-1129 trial, the median time to response was about 12 weeks, at the first scheduled check. Your transplant team will keep checking your response over the first few months. If symptoms are improving, they may begin tapering your steroid dose. If you are tolerating ibrutinib without major side effects, you would usually continue at the 420mg dose. If side effects emerge (most commonly bruising, diarrhea, or fatigue), your team may reduce the dose rather than stop entirely. About 26% of people in the trial needed a dose reduction for side effects, which is relatively common and does not necessarily mean the drug is failing.

Get in touch with your transplant team if you notice

Fast or irregular heartbeat, dizziness, fainting, chest discomfort, new shortness of breath, or swollen ankles (possible heart rhythm or heart failure problem; call your team promptly)
Unusual or severe bleeding: nosebleeds that won't stop, blood in stool, or large bruises from minor bumps (ibrutinib impairs platelet function beyond what the count shows)
Fever, chills, or productive cough (pneumonia occurred in 21% of people in the cGVHD trial, so prompt treatment matters)
Severe mouth sores that prevent eating or drinking
Stomach pain, dark urine, or yellow skin or eyes (possible liver problem; call your team right away)
New or rapidly worsening GVHD symptoms despite starting ibrutinib

Questions to take to your next visit

Should I avoid any medications or supplements that interact with ibrutinib? (Ibrutinib interacts with certain antifungals and antibiotics common in transplant patients.)
Do I need to stop or avoid aspirin, fish oil, or blood thinners while on ibrutinib?
Should I have an ECG before starting to check my heart rhythm?
What is the plan for monitoring my blood counts and liver enzymes?
When can we discuss starting a steroid taper?

See Chronic Graft-Versus-Host Disease trials enrolling now

Every stage of Ibrutinib treatment at a glance

Starting ibrutinib Start to 1 mo

Early response evaluation 1 mo to 3 mo

You have been on ibrutinib for 1-3 months. Your team is evaluating your initial response. In the pivotal trial, the overall response rate was 67%. Among people whose cGVHD responded, the skin improved in 88%, the mouth in 88% and the gut in 91% of those with that area affected, according to the trial paper by Miklos and colleagues. Your team is tracking your organ scores and symptoms using the NIH scoring system. If you are responding, you have likely noticed some improvement in daily functioning, such as easier eating, less skin tightness, or less mouth pain. If you are on corticosteroids, your team may have started tapering them.

For patients responding well: the goal is sustained response and steroid tapering. In the trial, 71% of responders maintained their response for 20 weeks or longer, which is an encouraging sign of durability. For patients with partial improvement: your team will likely continue ibrutinib for at least 3-6 months before concluding it is not working, since responses can deepen over time. For patients not responding: if you have seen no improvement by 3 months, your doctor will discuss alternatives. Other approved options include ruxolitinib, belumosudil and axatilimab. Each one works on a different pathway, and your team can explain which fits your case. If you are experiencing intolerable side effects like persistent diarrhea, bleeding, or cardiac issues, your team may switch to a different agent even if your GVHD is responding.

Formal response assessment 3 mo to 6 mo

This is the formal evaluation window. Your transplant team has enough data to determine whether ibrutinib is controlling your cGVHD. They are comparing your current NIH organ scores to baseline and assessing your overall functional status. By this point, your response trajectory is fairly clear. In the clinical trial, most responders had achieved at least partial response within the first few months. If you are responding and tolerating ibrutinib, you are in a good position for long-term management. If your response is partial, your team is weighing whether the level of improvement you have achieved is enough to continue or whether escalation is needed. Steroid tapering progress is also an important marker: if you have been able to lower your steroid dose by a good amount, that itself is a valuable outcome even if your GVHD has not completely resolved.

Patients with complete or significant partial response will continue ibrutinib with less frequent monitoring (every 1-3 months). Steroid tapering continues with the goal of reaching the lowest effective dose or discontinuation. If you are in complete response on both ibrutinib and low-dose or no steroids, you may eventually be a candidate for ibrutinib tapering, but this is usually not attempted until you have been in sustained remission for at least 6-12 months. For patients with inadequate response: switching to or adding another agent is the next step. Your team will factor in which organs are most affected when choosing the next therapy. Sclerotic or fibrotic disease may respond better to belumosudil. Broadly refractory disease is the setting where axatilimab has shown strong results.

Stable treatment 6 mo to 18 mo

You have been on ibrutinib for 6 months or longer and your cGVHD is either controlled or you have transitioned to a different management strategy. If ibrutinib is working, your monitoring schedule has likely settled into visits every 2-3 months with blood counts and assessment of GVHD activity. Your steroid dose is hopefully at a low level or discontinued. The focus during this phase is maintaining the response, managing chronic side effects, and attending to overall survivorship care: bone health (if you were on steroids for a long time), infection prevention (vaccinations when appropriate), and cancer surveillance.

If your GVHD has been in sustained response for 6-12 months and you are off steroids, your team may begin discussing whether to try tapering ibrutinib. There is no standard protocol for this; it is an individualized decision based on the severity of your original GVHD, how quickly you responded, and how much residual disease activity your team suspects. The label has no taper schedule for cGVHD. Some teams step down through lower doses such as 280mg and then 140mg while watching for a flare. Some patients can eventually discontinue successfully, while others need long-term maintenance therapy. A flare during taper is manageable by returning to the effective dose.

Long-term management 18 mo on

You are in the long-term phase of ibrutinib therapy or post-ibrutinib management. Some patients remain on a maintenance dose of ibrutinib for years because their GVHD requires ongoing suppression. Others have successfully tapered off and are in sustained remission. Either way, your care now focuses on survivorship: managing any permanent organ damage from GVHD (dry eyes, restricted lung function, skin changes, joint contractures), maintaining appropriate cancer surveillance, and optimizing overall health. Your transplant team and primary care doctor share responsibility for your long-term follow-up.

Long-term monitoring continues with visits every 3-6 months. Annual screening should include dermatologic evaluation for skin cancer, pulmonary function tests if you had any lung GVHD, ophthalmologic exams for dry eye management, and age-appropriate cancer screening. If you are still on ibrutinib, periodic ECGs are reasonable given the atrial fibrillation risk. If your GVHD flares after years of stability, re-starting ibrutinib (if you had stopped) or adding another agent is possible. The cGVHD treatment landscape continues to expand, and newer agents may offer better options for managing residual or relapsed disease.

This timeline shows typical patterns from the prescribing information, guidelines and published studies. Your own treatment may differ, and your transplant team is the source of truth for your plan. Last checked against the FDA label on November 7, 2026.

Sources

Clinical trial results

The Phase 1b/2 PCYC-1129 trial enrolled 42 patients with steroid-refractory cGVHD. The overall response rate was 67%. Among the people who responded, 88% of those with skin disease, 88% of those with mouth disease and 91% of those with gut disease saw that organ respond^[2]. In the iMAGINE trial (NCT03790332) of 47 children and young adults aged 1 to 21, 60% responded by week 25, which supported the 2022 approval for children^[4].

Sustained responses lasting 20 weeks or more occurred in 71% of responders. These results led to the first-ever FDA approval of a drug specifically for cGVHD in August 2017.

Development history

Ibrutinib was developed by Pharmacyclics as a BTK inhibitor for B-cell cancers, gaining its first FDA approval for mantle cell lymphoma in November 2013, followed by CLL in 2014. Mouse studies published in 2014 (Dubovsky and colleagues, Journal of Clinical Investigation) found that BTK and ITK are needed for cGVHD to develop, and that ibrutinib eased the disease^[5].

This led to clinical testing in cGVHD patients, and FDA approved ibrutinib for cGVHD on August 2, 2017, making it the first drug ever specifically approved for this condition. It is also approved for CLL/SLL and Waldenström macroglobulinemia. Its US indications for mantle cell lymphoma and marginal zone lymphoma were withdrawn in 2023 and no longer appear on the label. In August 2022 the cGVHD indication was extended to children 1 year and older.

Ask anything about Ibrutinib

AI-powered answers from clinical trial databases, FDA reports, and medical literature

Start withor ask

Explore Chronic Graft-versus-Host Disease and Waldenström Macroglobulinemia trials

Other Chronic Graft-versus-Host Disease & Waldenström Macroglobulinemia treatments

Common questions about Ibrutinib

▸What is Ibrutinib (Imbruvica)?

The first FDA-approved drug specifically for chronic graft-versus-host disease (cGVHD), approved in August 2017 for people whose cGVHD has not responded well enough to at least 1 earlier treatment, and for children 1 year and older since August 2022. Ibrutinib blocks BTK, a protein that switches on B cells, and also ITK in T cells. It is also approved for adults with Waldenström macroglobulinemia, alone or with rituximab, and for chronic lymphocytic leukemia.

▸How does Ibrutinib work?

With BTK blocked, B cells cannot produce the tissue-attacking antibodies. With ITK blocked, the pathogenic T cell subsets calm down.

▸What are the side effects of Ibrutinib?

Common side effects include fatigue, diarrhea, bruising, low platelets (thrombocytopenia), mouth sores, muscle spasms, nausea, bleeding, anemia, and pneumonia. More serious effects can include severe infections (pneumonia occurred in 21% of adults in the main trial and was serious in 14%) and bleeding events. About 24% of patients discontinued treatment due to side effects, and 26% required dose reductions. The label also warns about serious bleeding, infections, heart rhythm problems, heart failure and sudden death, high blood pressure, low blood counts, second cancers, liver injury, tumor lysis syndrome (a dangerous chemical imbalance when many cells break down at once), and harm to an unborn baby.

▸How is Ibrutinib taken?

For patients 12 and older, 420mg by mouth once daily (capsules or tablets). Children 1 to under 12 years take 240mg/m2 once daily (up to 420mg), and an oral suspension is available. For cGVHD, treatment continues until the cGVHD worsens, the original cancer comes back or side effects become too much, and the doctor stops it once it is no longer needed. For Waldenström macroglobulinemia, adults take 420mg once a day, alone or with rituximab. The label says to avoid grapefruit and Seville oranges. Posaconazole and voriconazole, antifungal medicines often used after a transplant, call for a lower ibrutinib dose, and the label advises against most other strong CYP3A inhibitors^[4].

▸Is Ibrutinib FDA approved?

Yes, Ibrutinib (Imbruvica) is FDA approved (2017) for the treatment of Chronic Graft-versus-Host Disease and Waldenström Macroglobulinemia.

▸Was ibrutinib the first drug approved for chronic GVHD?

Yes. Ibrutinib (Imbruvica) became the first FDA-approved drug specifically for chronic GVHD on August 2, 2017, after failure of one or more prior lines of therapy, marking a turning point from corticosteroid-only treatment to targeted therapy. In August 2022 the cGVHD indication was extended to children 1 year and older. ^[1]

▸How does ibrutinib work differently from ruxolitinib in GVHD?

Ibrutinib blocks BTK in B cells and ITK in T cells, targeting both arms of the adaptive immune attack. Ruxolitinib blocks JAK1/JAK2, reducing inflammatory cytokine signaling more broadly. No head-to-head trial has compared ibrutinib with ruxolitinib in chronic GVHD. ^[1]^[2]

▸How is Imbruvica taken for chronic GVHD?

For patients 12 and older, Imbruvica (ibrutinib) is taken by mouth as 420mg once daily in capsules or tablets. Children 1 to under 12 years take 240mg/m2 once daily up to a maximum of 420mg, and an oral suspension is available. Treatment continues until the cGVHD worsens, the original cancer comes back or side effects become too much. The label says to avoid grapefruit and Seville oranges, and some antifungal medicines such as posaconazole and voriconazole call for a lower dose. ^[1]

▸What are the side effects of ibrutinib in chronic GVHD?

Common side effects of ibrutinib (Imbruvica) include fatigue, diarrhea, bruising, low platelets, mouth sores, muscle spasms, nausea, bleeding, anemia, and pneumonia, which occurred in 21% of adults in the main trial and was serious in 14%. About 24% of patients discontinued treatment because of side effects and 26% needed dose reductions. The label also warns about serious bleeding, infections, heart rhythm problems, heart failure and sudden death, high blood pressure, low blood counts, second cancers, liver injury, tumor lysis syndrome, and harm to an unborn baby. ^[1]^[2]

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

U.S. Food and Drug Administration · August 2, 2017. FDA expands ibrutinib indications to chronic GVHD. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-ibrutinib-indications-chronic-gvhd
Blood (American Society of Hematology). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. https://pmc.ncbi.nlm.nih.gov/articles/PMC6033048/
Pharmacyclics / AbbVie. IMBRUVICA Patient Support. https://www.imbruvica.com/imbruvica-by-your-side
U.S. National Library of Medicine, DailyMed. IMBRUVICA (ibrutinib) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44
Journal of Clinical Investigation · 2014. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. https://pubmed.ncbi.nlm.nih.gov/25271622/